HOME >> BIOLOGY >> NEWS
Molecular basis of mental retardation uncovered

Scientists at last may have determined how mental retardation develops in people with fragile X syndrome, a condition caused by the inherited loss of an essential protein, termed the fragile X mental retardation protein (FMRP). The new research demonstrates that FMRP controls the fate of several specific proteins in brain cells and thus may explain why the absence of this single protein can cause the range of physical, cognitive and behavioral abnormalities characteristic of fragile X syndrome.

While these findings may not lead to a cure for fragile X syndrome, they do offer the potential for future therapies that would lessen the impact of the disease.

"This work represents a new understanding of mental retardation," says Robert B. Darnell, M.D., Ph.D., a principal investigator of the current research and a professor at The Rockefeller University. "Our findings suggest entirely new ways of thinking about treating the problems these patients have."

Katie Clapp, president of the FRAXA Research Foundation, which largely funded Darnell's work, and mother of two children with fragile X says, "For the first time, scientists can explain why these children experience certain symptoms. This kind of knowledge is very reassuring to the families of children with the disorder."

The latest research, reported in two papers appearing in the Nov. 16 issue of Cell, was conducted by scientists at The Rockefeller University in collaboration with researchers from the Emory University School of Medicine. One study was initiated by Darnell, head of the Laboratory of Molecular Neuro-Oncology at Rockefeller, and the other by Stephen T. Warren, Ph.D., an investigator at Emory University School of Medicine and Howard Hughes Medical Institute.

Fragile X syndrome, the second leading cause of mental retardation after Down syndrome and the most common cause of inherited mental retardation, affects approxim
'"/>

Contact: Whitney Clavin
clavinw@rockefeller.edu
212-327-7900
Rockefeller University
15-Nov-2001


Page: 1 2 3 4

Related biology news :

1. Molecular motor implicated in tissue remodeling
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Molecular staples shape a cancer killer
5. Molecular motor myosin VI moves hand over hand, researchers say
6. Molecular therapeutics advance fight against brain cancer
7. Molecular motor shuttles key protein in response to light
8. Molecular traffic cop directs cellular signals
9. Molecular marker predicts success of breast cancer treatment
10. Molecular image of genotoxin reveals how bacteria damage human DNA
11. Molecular mechanism found that may improve ability of stem cells to fight disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Molecular basis mental retardation uncovered

(Date:8/12/2015)... YORK , Aug. 12, 2015  New ... hackers can attack Android phones to steal users, ... the increasing availability of fingerprint scanners on mobile ... utmost concern. To secure biometrics on mobile devices, ... to augment these convenient authentication systems with strong ...
(Date:8/6/2015)... 6, 2015  Today, U.S. Congressman Mike ... ™ to learn firsthand how Silicon Valley technologies ... is a world leader in multi-factor identity management ... helping federal agencies and commercial organizations achieve new ... "The vast majority of network breaches can ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has announced the ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Middle East & Africa Biomedical Sensors ... a CAGR of 3.26% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:8/31/2015)... Aug. 31, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... the 30-day review period following the filing of ... indications with the U.S. Food and Drug Administration ... active. Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2015 ... on the discovery and development of novel cancer immunotherapies, ... , M.D., Ph.D., as Chief Executive Officer and ... Drs. Wong and Ho join an experienced management team ... company: Jordan Fridman , Ph.D., Chief Scientific Officer; ...
(Date:8/31/2015)... ... 31, 2015 , ... Regulatory agencies have acknowledged impurities especially ... process. Thus, innovator companies must understand what will be needed in the drug ... been hosting multiple educational panels and seminars for experts to share advice concerning ...
Breaking Biology Technology:Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
Cached News: